Compare Essex Property Trust, Inc. (ESS) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Essex Property Trust, Inc. vs Johnson & Johnson — how do they compare? Essex Property Trust, Inc. trades at $272.94 (market cap $17.26B), while Johnson & Johnson trades at $260.45 (market cap $618.09B). The key difference: Johnson & Johnson is far larger — about 35.8× Essex Property Trust, Inc.'s market cap, and Essex Property Trust, Inc. pays the higher dividend (3.86%). Which is the better fit depends on your goals — on Pluang, investors hold Essex Property Trust, Inc. for 111 Days and Johnson & Johnson for 129 Days on average.
| ESS | JNJ | |
|---|---|---|
Market Cap | $17.26B | $618.09B |
Volume | 454,464 | 6,050,983 |
Sector | Real Estate | Health |
52-Week High | $298.33 | $278.43 |
52-Week Low | $239.61 | $186.00 |
Typical Hold Time | 111 Days | 129 Days |
Enterprise Value | $23.86B | $646.37B |
Dividend Yield | 3.86% | 2.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ESS trades at $273.21, up 1.93% today, but technical indicators signal a bearish trend with resistance near $273. The company reported mixed quarterly earnings, beating in Q1 but missing in Q2 and Q4 2025, while maintaining strong profitability with a net margin of 21.48%. Recent news highlights strong Q2 2026 results and the resolution of litigation, improving the risk profile.
The outlook is cautiously optimistic with a consensus price target of $303.41, implying upside, but risks include earnings volatility and high debt levels. Investor sentiment is mixed, with analysts predominantly holding a neutral stance amid ongoing operational execution challenges in the real estate sector.
Johnson & Johnson (JNJ) trades at $259.62, up 0.45% with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with 21.48% net margin and 25.74% ROE, though valuation ratios appear elevated with P/E at 29.75. Recent news highlights growth in the Innovative Medicine segment and positive analyst coverage with 52.5% buy ratings.
JNJ offers stable dividend income and pharmaceutical innovation upside, but faces patent cliff risks and increasing debt-to-asset ratio (24.06% in 2025). Analyst consensus target of $286.53 suggests 10% upside potential, though technical resistance at $260 may limit near-term gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Essex Property Trust, Inc.
Essex Property Trust owns a portfolio of 253 apartment communities with over 62,000 units and is developing three additional properties with 571 units. The company focuses on owning large, high-quality properties on the West Coast in the urban and suburban submarkets of Southern California, Northern California, and Seattle.
Read more on ESS →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
